Just in Time
...blood substitute market competition may crop up (As released it would have the advantage of having a very visible and reputed brand and it would benefit from this by means of easier market penetration as it would be able to use the already existing distribution channels and goodwill of Biopure corporation.As for the costs as already mentioned to penetrate the human blood market the pricing should be about $ 400 rather than $ 700 so as to achieve market penetration. First of all consumers would be ready to pay more for Hemopure as human life is perceived to be more valuable than animal life. Also if required the company can stress effectively on the process difference between making of Hemopure and Oxyglobin. BioPure Corporation, which was founded in 1984 by entrepreneurs Carl Rausch and David Judelson, is a privately owned biopharmaceutical firm specializing in the ultra purification of proteins for human and veterinary use. In 1998 Biopure pioneered the development of oxygen therapeutics using “Hemoglobin”, a new class of pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new Oxygen based treatment approach for managing patients' oxygen requirements in a broad range of potential medical applications. The factor distinguishing Biopure’s two products from other blood substitute products being developed by two ...